Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed

The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed. Patients treated with Aimovig, reported significant reductions in monthly migraine days and a substantially improved ability to take part in daily activities vs placebo -   Tolerability and safety profile of Aimovig was similar to placebo, in line with data seen across the clinical trial program of over 3,000 patients  -   Aimovig is the first and only FDA and EMA approved CGRP-targeted therapy specifically designed for migraine prevention The digital press release with multimedia content can be accessed here: Basel, October 23, 2018 - Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet . Patients treated with Aimovig had significant improvements on all primary and secondary endpoints of the study. Aimovig is specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine. "These findings provide real hope for patients who have been suffering for years with the pain and disability of migraine while cycling through numerous treatment options due to lack of efficacy or intolerable side effects." said Prof. Uwe Reuter, Managing Medical Director at Charité Universitätsmedizin.